Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 4, 2013, Pages 507-515

  Karras, Spyridon ^a   Pontikides, Nikolaos ^a   Krassas, Gerasimos E ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

Cabozantinib; Medullary thyroid cancer; Thyroid cancer; Tyrosine kinase inhibitor

Indexed keywords

AMUVATINIB; AXITINIB; CABOZANTINIB; COMETRIQ; FORETINIB; GEFITINIB; LENVATINIB; MOTESANIB; PAZOPANIB; PLACEBO; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; ROSIGLITAZONE; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2; XL 999;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CELL PROLIFERATION; DIARRHEA; DISTANT METASTATIC THYROID CANCER; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOCALCEMIA; MAXIMUM TOLERATED DOSE; MEDULLARY THYROID CANCER; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PALMAR ERYTHRODYSESTHESIA; PALMAR PLANTAR ERYTHEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; THYROID CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ANILIDES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84875129546     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.780028     Document Type: Article

References (56)

1. SEER Stat Fact Sheets: thyroid. National Cancer Institute; Bethesda, MD. 2011.Available from: http://seer.Cancer. gov/statfacts/html/thyro. html#incidencemortality [Last accessed 10 December 2012]
2. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon; 2004
3. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152-61
4. Li N, Du X, Reitzel L, et al. Impact of enhanced detection on the increase in thyroid cancer incidence in the US: review of incidence trends by socioeconomic status within the Surveillance, Epidemiology, and End Results registry, 1980-2008. Thyroid 2013;23(1):103-10
5. Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 2007;177:1357-61
6. American Thyroid Association (ATA) guidelines taskforce on thyroid Nodules and differentiated thyroid cancer. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
7. Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7): vii110-19
8. Kloos RT, Eng C, Evans DB, et al. American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612
9. Panigrahi B, Roman SA, Sosa JA. Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol 2010;17:1490-8
10. Maruyama R, Suzuki H, Yamamoto E, et al. Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. Tumour Biol 2012;33:277-85
11. Trosko JE, Chang CC, Upham BL, Tai MH. Ignored hallmarks of carcinogenesis: stem cells and cell-cell communication. Ann N Y Acad Sci 2004;1028:192-201
12. Romitti M, Ceolin L, Siqueira DR, et al. Signaling pathways in follicular cell-derived thyroid carcinomas. Int J Oncol 2013;42:19-28
13. Cerrato A, De Falco V, Santoro M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 2009;43:143-55
14. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313
15. Perez CA, Santos ES, Arango BA, et al. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck 2012;34:736-45
16. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012;2:a006502
17. Capp C, Wajner SM, Siqueira DR, et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010;20:863-71
18. Ramirez R, Hsu D, Patel A, et al. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2000;53:635-44
19. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6
20. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60
21. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-7
22. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72
23. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-71
24. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA) 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 2010;28(15 Suppl):5503
25. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2012;18:3722-30
26. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897-905
27. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
28. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42
29. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13
30. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30
31. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
32. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
33. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer-a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22
34. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349
35. Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19:209-16
36. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8
37. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72
38. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011;7:617-24
39. Shapiro GI, McCallum S, Adams LM, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs 2012;
40. Tibes R, Fine G, Choy G, et al. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;
41. Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc) 2011;47:857-68
42. Exelixis XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib. Exelixis, Inc.; San Francisco, CA. 2012. Available from http://www. exelixis.com/investors-media/press-releases [Last accessed 10 December 2012]
43. ClinicalTrials.gov, A service of the U.S. National Institutes of Health, Bethesda, MD. 2012. Available from: http://www.clinicaltrials.gov/ct2/results? term=cabozantinib&Search=Search [Last accessed 10 December 2012]
44. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6
45. Full prescribing information. Cometriq, Exelixis, Inc., San Francisco, CA. Available from: http:/www.cometriq.com/downloads/Cometriq-Full-Prescribing- Information.pdf [Last accessed 10 December 2012]
46. Choueiri TK, Pal SK, Cabanillas ME, et al. Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC) 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011;29(Suppl 15):e13042
47. Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects. ClinicalTrials. gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012.Available from: http://clinicaltrials. gov/ct2/show/NCT01493869? term=NCT01493869&rank=1 [Last accessed 10 December 2012]
48. Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies. ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012. Available from: http://clinicaltrials.gov/ct2/show/ NCT00215605?term=renal+elimination +AND+cabozantinib&rank=1 [Last accessed 10 December 2012]
49. Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan. ClinicalTrials. gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012; Available from: http://www. clinicaltrials.gov/ct2/results? term=cabozantinib&Search=Search [Last accessed 10 December 2012]
50. Torres KE, Zhu QS, Bill K, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011;17:3943-55
51. You WK, Sennino B, Williamson CW, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011;71:4758-68
52. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308
53. Verbeek HH, Alves MM, de Groot JW, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011;96:E991-5
54. Cabanillas ME, Brose MS, Ramies DA, et al. Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC) 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(Suppl 15):5547
55. Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM). ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012.Available from: http://www. clinicaltrials.gov/ct2/show/ NCT00704730? term=NCT00704730&rank=1 [Last accessed 10 December 2012]
56. Schoffski P, Elisei R, Müller S, et al. EXAM Study Group. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(Suppl 15):5508